Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents

MET is a receptor tyrosine kinase known for its pleiotropic effects in tumorigenesis. Dysregulations of MET expression and/or signaling have been reported and determined to be associated with inferior outcomes in breast cancer patients rendering MET a versatile candidate for targeted therapeutic int...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayoub, Nehad M, Al-Shami, Kamal M, Alqudah, Mohammad A, Mhaidat, Nizar M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634371/
https://www.ncbi.nlm.nih.gov/pubmed/29042798
http://dx.doi.org/10.2147/OTT.S148604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634371/
https://www.ncbi.nlm.nih.gov/pubmed/29042798
http://dx.doi.org/10.2147/OTT.S148604

Ejemplares similares